What should I do if I develop resistance to Ensifentrine while taking Ohtuvayre (Ensifentrine)?

If a patient develops resistance while taking Ohtuvayre (Ensifentrine)-Ensefentine, this resistance needs to be identified and evaluated in a timely manner. Patients may experience worsening symptoms such as difficulty breathing, increased coughing, or other discomfort. At this time, the doctor should conduct a detailed medical history and physical examination, combined with pulmonary function tests and other examinations, to determine whether the patient's response to exefantine has declined.

Once resistance is confirmed, the doctor's first priority is to adjust the treatment plan. First, a combination drug strategy can be considered. Adding other types of drugs, such as long-acting bronchodilators or anti-inflammatory drugs, to exefentine can enhance the therapeutic effect through different mechanisms and may overcome the problem of drug resistance. Combining drugs can not only improve the efficacy, but also reduce the side effects of a single drug.

Secondly, optimizing medication regimens is also an important method to deal with drug resistance. Doctors can adjust the dosage and administration frequency of ensefentin based on the patient's specific conditions, or even consider switching to other similar drugs. Individualized treatment plans can more effectively meet patient needs, thereby improving overall outcomes.

In addition, it is important to strengthen patient self-management and education. Patients should be informed on how to use exefantine correctly, including taking the medicine on time and paying attention to changes in their symptoms. Improving patient compliance helps maximize the efficacy of drugs and reduce the chance of drug resistance. At the same time, patients should also be aware of the early signs of drug resistance so that they can seek timely medical help.

In some cases, doctors may recommend further testing, such as secretion culture or genetic testing, to identify mechanisms of resistance. These test results help doctors develop more targeted treatment plans.

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC10392818/